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Each year, approximately 250000 women die during pregnancy, delivery, or postpartum. Maternal mortality rates due to
tuberculosis (TB) and HIV in Sub-Saharan Africa now supersede obstetric-related causes of mortality. The majority of cases
occur in population-dense regions of Africa and Asia where TB is endemic. The vertical transmission rate of tuberculosis is 15%,
the overall vertical transmission rate of HIV in resource-limited settings with mono- or dual-ARV therapy varies from 1.9% to
10.7%. If the millennium development goals are to be achieved, both HIV and TB must be prevented. The essential aspect of TB
prevention and detection in the newborn is the maternal history and a positive HIV status in the mother. Perinatal outcomes are
guarded even with treatment of both diseases. Exclusive breast feeding is recommended. The community and social impact are
crippling. The social issues aggravate the prognosis of these two diseases.
1.BurdenofDisease
Each year, approximately 250 000 women die during preg-
nancy, delivery, or postpartum. Maternal mortality rates due
to tuberculosis (TB) and HIV in Sub-Saharan Africa now
supersede obstetric-related causes of mortality [1].
There has been a global increase of tuberculosis in wom-
en due to the intersecting epidemics of HIV and TB. Since
1990, the number of TB cases has quadrupled in some
regions of Africa and 75% of TB patients are HIV infected
[2].
HIV and TB aﬀect women in the prime child bearing age
range of 15–29 years, contributing to an increased mortality
in this age group [3].
TB and HIV are independent risk factors for maternal
mortality. In Sub-Saharan Africa, 3-4% of HIV infected
mothers die within a year of parturition [3–5].
A signiﬁcant increase in tuberculosis in pregnant women
was shown by an increasing caseload from 0.1% to 0.6%
between 1996 and 1998 in Durban South Africa. Of these
mothers with TB, 115 (78.8%) were HIV infected, 26
(17.8%) were uninfected. The minimum TB/HIV coin-
fection rates increased from 36.4% in 1996 to 88.3% in
1998 (P<. 001). The TB prevalence rate for HIV nonin-
fected maternities at King Edward VIIIth Hospital Durban
was 72.9/100000 and for the HIV infected maternities
774/100000 with a relative risk of TB due to HIV infection
of 10.62 [6]. The mortality rate in the TB infected mothers
was 103/10000 with 14 of the 15 mothers who died being
HIV infected [6].
Epidemiological indicators of TB indicate that the Mil-
lennium DevelopmentGoal of TB elimination by 2050 is not
likelytobeachieved.Themajorityofcasesoccur,asindicated
above, in population-dense regions of Africa and Asia where
TB is endemic. The persistence of TB in the setting of poor
existing health infrastructure has led to an increase in drug-
resistant cases, the majority associated with HIV coinfection
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Unfortunately HIV inﬂuences the presentation of TB in
a number of ways. Smear negative cases are more common
i nt h o s ew h oa r eH I Vi n f e c t e d[ 8]. In addition, the lower
bacterial load and the atypical chest radiographic ﬁndings
add to the diﬃculty of arriving at a diagnosis of TB [9].
The pathological features of TB in HIV-infected women
diﬀer from those without HIV. The TB granulomas in the
lung of HIV-positive individuals show extensive necrosis,
poorly formed granulomas, and an inﬁltration of poly-
morphonuclear cells. TNF was greatly reduced in TB/HIV
co-infected individuals suggesting that HIV through TNF
alters the immune response leading to impairment of the
antituberculosis response [10]. In TB meningitis HIV pos-
itive individuals have reduced inﬂammatory responses and
extensive vasculitis [11].
2.VerticalTransmissionof TB
The fetus and newborn of the pregnant woman with TB
are exposed to the disease and may become infected. The
extrapulmonary forms of the disease, miliary and meningeal
TB, are greater risk factors for congenital TB [8]. On the
other hand, vertical transmission did not occur if mothers
had pleural eﬀusion, generalized adenopathy.
In Durban, South Africa 15% of the mothers with TB
transmitted the organism to their infants in the ﬁrst three
weeks of life. Mothers with TB diagnosed prenatally, trans-
mitted TB in the ﬁrst week of life. Infants whose mothers
with TB diagnosed in late pregnancy or the immediate
postpartum period presented with TB in the third week of
life. Mothers who did not receive prenatal care transmitted
TB more readily to their infants as did mothers who were
nonadherent to TB therapy [12].
3.VerticalTransmissionof HIV
The vertical transmission rate of HIV documentedin a study
conducted in Durban South Africa in the 199Os was 34%
[13].
In current studies of routine neonatal followup of 588
well term infants at a local clinic, the PCR at six weeks
indicated the overall transmission rate was 10.7% (63/588),
with dual therapy (maternal AZT antenatally and a single-
dose nevirapine at the onset of labour, and baby receiving
a single dose of nevirapine, the transmission rate and PCR
testing at 6 weeks and 9 months was 1.9% (3/154). In
mothers and babies taking a single dose of nevirapine only
the transmission rate was 12.8% (49/382), and if no ARV,
AZT, or nevirapine was taken, the transmission rate was
22.4% (11/49). Dual therapy resulted in an 82% reduction
in transmission (RR 0.18 [CI 0.07–0.49] Maternal ARV
exposure and transmission rate was highly signiﬁcant (P<
.0001) [14].
Preliminary results in a follow-up study of 457 high risk
infantsbothterm(birthweight>2500gms,n = 165)andlow
birth weight (birth weight <2500gms, n = 292) from King
Edward VIIIth Hospital, Durban South Africa, 2 (0.4%) of
the term infants died and 11 (2.4%) of the low birth weight
infants died. The HIV transmission rate in the term infants
was 9.1% and in the low birth weight were 13%. Some of the
mothers were on monotherapy and some on dual therapy.
The mean CD4 count of the mothers whose babies died and
in those babies that required ARVS based on positive PCRs
at 6 weeks was 303cells/mm3 [15].
Eﬀective prevention of mother-to-child transmission
(PMTCT) strategies can now decrease HIV transmission to
less than 1%, not only during the intrauterine and intra-
partum period but also during breastfeeding [16]. The most
eﬃcacious method ofensuring bothoptimal maternal health
and reducing transmission risk to the infant is the use of
maternal HAART[17]. However, the use of HAARTin preg-
nancy is associated with an increased incidence of preterm
delivery and low birth weight, which requires monitoring
during the pregnancy [18].
TheeﬀectofHIV-associated immunodeﬁciencyismarked
in infants as demonstrated by blunted Cytotoxic T-lympho-
cyte (CTL) responses in HIV-infected infants particularly if
infected early during the pregnancy [19]. These immuno-
logical eﬀects are manifested by decreased CD4 counts in
both premature and term infants at birth and by a rapid
decline in the CD4 count over the ﬁrst 6 months of life
[20, 21].
The above unpublished studies in low birth weight in-
fants need to be veriﬁed in further studies.
4.ClinicalFeaturesof TBand HIV in
Pregnant Women
TB in pregnant women presents with the same clinical fea-
tures as the nonpregnant women [22, 23].
The clinical spectrum of the signs of TB may vary from
mild cough, fever, and fatigue to overt signs of weight
loss and gross radiological changes [24]. The diagnoses of
TB and HIV may be delayed by the common symptoms
of malaise and fatigue of pregnancy. Extrapulmonary TB
occurs in 10–15% of pregnant women with TB [25]. The
chest radiograph may reveal the radiological features of
TB in an asymptomatic mother [26]. The crucial aspects
of the diagnosis are a previous history of TB, current
history of TB receiving therapy, a contact at home, persistent
cough for two weeks or more, and an unresolving pneu-
monia.
Maternal genital TB is subclinical and may be considered
when there is no overt TB in the mother and TB is diagnosed
in the baby [6].
Tuberculosis and HIV in pregnancy may have three
presentations; ﬁrstly, a pregnant woman develops tubercu-
losis and is found to be HIV infected and therefore will
require treatment for both diseases; secondly, tuberculosis is
diagnosed in an HIV-infected mother who does not herself
require antiretroviral therapy but for the prevention of
mother-to-child transmission of HIV; thirdly overt signs of
TB mayappear in an HIV-infected pregnant woman who has
commenced HAART[24]. This may be an immune reconsti-
tution infection syndrome (IRIS) following exacerbation or
aggravation of underlying TB [27].International Journal of Pediatrics 3
5.ClinicalFeaturesofTuberculosis
intheNewbornPeriod
The essential aspect of TB prevention and detection in the
newborn is the maternal history. A positive HIV status in the
motherincreases the likelihood ofTB in the mother[28, 29].
The critical points in the maternal history are given in the
section above “Clinical Features of TB and HIV in pregnant
women”. Transmission and outcomes are deﬁnitely aﬀected
by duration of therapy before delivery. Fourmonths or more
oftherapyisprotectivetothefetus.However,noncompliance
with therapy carries an increased risk of transmission of the
Mycobacterium tuberculosis to the infant [6].
Symptoms of tuberculosis in the neonate are usually in
the low birth weight, growth-retarded infant and are non-
specific including lethargy, poor feeding, poor weight gain
and unresolving or recurrent pneumonia. Signs and symp-
toms may be present at birth but overt expression of the
disease more often occurs in the second or third week of life
when respiratory problems, hepatosplenomegaly, and lym-
phadenopathy are present [30]. Other clinical features may
include skin lesions, seizures, jaundice, ear discharge, par-
avertebralabscess, andhaematologicalanomaliesandascites.
Although the signs may suggest chronic intra-uterine infec-
tion and they may also mimic acute infection, depending on
the clinical phase and severity of the disease. The diagnosis
may be diﬃcult and therefore missed [31]. In a setting
of poor response to antibiotics and supportive therapy
and when microbiological evaluations for acute infections
and serological tests for chronic intrauterine infections are
negative, tuberculosis should be considered, particularly if
the mother is known to be infected with HIV.
Theabovephysicalsignsofchronicintrauterineinfection
may represent the features of TB and coinfections such as
cytomegalovirus infection setting a stage for rapidly progres-
sive disease [32].
6.BCG andthe HIV-Infected Infant
BCG is a live attenuated vaccine derived from Mycobac-
terium bovis. The vaccine is given to infants at or around
birth to provide protection from severe TB disease dur-
ing childhood (including TB meningitis and miliary TB)
however it gives no protection against lung disease. Several
distinct strains of BCG derived from the original BCG
strain are used inimmunization programs around theworld,
each with varying immunogenicity and side eﬀect proﬁle.
With over 90% estimated vaccine coverage, especially in TB
endemic regions, BCG is the most frequent administered
vaccine globally with over 100 million doses administered
annually [33].
WiththeoverlapofhighTBandHIVprevalentcountries,
BCG is also given in areas of high HIV incidence. While the
risks of adverse events associated with BCG vaccination in
HIV-negative infants are low (<0.04% for local disease and
0.0002%fordisseminateddisease),HIV-positiveinfantshave
a markedly increased risk ofdevelopinglocal (5.6%)and dis-
seminated BCG disease (BCGosis) (0.2%) [34]. The World
Health Organization (WHO) has therefore recommended
that BCG be only given to HIV-negative infants, however
implementationofthisrecommendationis impracticalwhen
BCG is given at birth and the HIV status has not been deter-
mined.
Clinical features associated with BCG disease include
local ulceration at the injection site, ipsilateral axillary lym-
phadenitis, and abscess formation and disseminated disease
with involvement of the lung, liver, and bone marrow. Dis-
seminated disease in HIV positive infants has a 75% mortal-
ity [35].
Management of BCGosis is a combination of antituber-
culosis drug therapy. BCG is resistant to pyrazinamide and
some strains are resistant to isoniazid (INH).
Drug therapy should include ARVSs and high dose INH,
Rifampicin, ethambutol, and a ﬂuoroquinolone for a min-
imum of 9 months. Careful monitoring for toxicity and
clinical response to treatment are important.
7.Investigationofthe Neonate
Criteria for investigation of TB are based, as indicated above,
on the maternal history, the physical signs in the newborn,
the failure to respond to antibiotics, and supportive therapy
and maternal HIV positivity [6].
Investigations are from multiple sites and may have to be
repeated. The chest radiograph is most often atypical of TB
and may be diﬃcult to interpret. Repeated radiographs may
show a more classical picture.
Specimens from the neonate suitable for microscopy and
culture include gastric aspirates, induced sputum, tracheal
aspirates if the neonate is mechanically ventilated, cere-
brospinal ﬂuid and, if seen on the chest radiograph, pleural
ﬂuid. Early morning gastric aspirates should be taken on
three consecutive days before the ﬁrst feed of the day [24].
If deemed appropriate, a liver or lymph node biopsy may be
undertaken for histology and culture of M. tuberculosis.I n
the event of death, relevant biopsies (e.g., liver, lung, nodes,
and skin lesions) should be taken,with maternal consent, for
histological and microbiological examination. Samples are
examined microscopically for acid fast bacilli and cultured
on standard media for 12 weeks [30]. If a neonate has skin
lesions or an ear discharge, specimens should be taken for
microbiological examination [31]. Induced sputum is more
likely to be positive on microscopy and culture than gastric
aspirates [36]. Broncho-alveolar lavage (BAL) has been
recognised as an important investigation in children and
this has been extrapolated to the newborn [37]. Detection
of M. tuberculosis DNA in BAL ﬂuid by polymerase chain
reaction (PCR) has been shown to be of value [38]. Newer
more rapidtestsforthediagnosisoftuberculosisareurgently
needed. The GeneXpert is a new test marketed to detect
active TB and rifampicin resistance within 90 minutes. This
testwillbeofimportanceincommunitieswithahighburden
of tuberculosis including MDR TB. However the test is
expensive and has to be made available at a lower cost [39].
Lineprobeassayisarapidmethodofdetectingsensitivity
in source cases for sensitivity [40].4 International Journal of Pediatrics
8.InvestigationsforTuberculosis
ofthe Newborn
(i) Chest radiograph.
(ii) Three early morning gastric aspirates/washings.
(iii) Induced sputum.
(iv) Endotracheal aspirate (if baby is mechanically venti-
lated).
(v) Cerebrospinal ﬂuid.
(vi) Blood culture for Mycobacterium tuberculosis.
(vii) Liver biopsy when indicated.
(viii) Lymph node biopsy when indicated.
(ix) Cultures of skin lesions or ear discharges.
(x) Bronchoalveolar lavage (BAL).
(xi) Polymerase chain reaction (PCR) on BAL ﬂuid.
(xii) Future tests GeneXpert
(xiii) Line probe assay.
In all babies who are exposed to or are diagnosed with TB,
HIV must be excluded. The cheapest is to test the mother by
the HIVElisa. If the mother isHIV positive, infection should
be conﬁrmed in the baby with the DNA PCR which has a
sensitivity of 38% at birth and 100% by two months and
six months. RNA PCR sensitivity is 47% at birth and 100%
sensitivity at 2 months and 6 months [41].
9.Investigationofthe Mother
Pregnant women with TB undergothesame investigations as
nonpregnant women and a HIV Elisa has to considered [20].
10.Managementofthe Baby withTBand HIV
10.1. Management of the Asymptomatic Newborn (TB). If
the newborn is asymptomatic and the mother is considered
to have the sensitive mycobacterium, the infant should
receive prophylaxis as soon as the investigations have been
completed. Prophylaxis is isoniazid (INH) 10mg/kg/day and
rifampicin 10mg/kg/day for 3 months [40]. The Bacille
Calmette-Gu´ erin vaccine (BCG) is withheld until com-
pletion of the period of prophylaxis. However, in some
situations where followup is not certain the BCG is given
on discharge from the neonatal unit (see above on BCG).
At the end of the 3 months the chest radiograph should be
repeated. In addition, the baby should be screened for other
coinfections such as cytomegalovirus, herpes simplex, and
herpes zoster. If, during the period of prophylaxis, the infant
develops signs that suggest TB or if the cultures are positive,
full anti-TB therapy should be commenced and continued
for 6 months. In HIV and TB high prevalence areas, prophy-
laxis may not oﬀer protection against acquisition of TB. If
the maternal HIV status is unknown the mother should be
tested.
10.2. Management of the Symptomatic Newborn. Ad i ﬀeren-
tial diagnosis of HIV, syphilis, cytomegalovirus, congenital
herpes, and atypical pneumonia (Mycoplasma pneumoniae)
shouldbeconsideredininfantswhopresentwiththephysical
signs indicated above [42]. On clinical suspicion, anti-TB
therapy should be commenced once the relevant samples for
tuberculosis have been taken.
Standard WHO, recommended drug regimens are INH
10mg/kg/day, RIF 10mg/kg/day and pyrazinamide
20mg/kg/day for two months followed by a four-month
course of INH and RIF [42]. Therapeutic response is de-
termined by the regression of clinical signs, weight gain,
improved appetite, and radiological resolution where ap-
plicable.
If the baby is HIV PCR positive, following two weeks of
anti-TB therapy or longer and depending on the clinical
condition of the infant and there are no side eﬀects
of treatment, ARVs may be commenced. The process of
commencingARVsis verydiﬃcult,particularly ifthemother
is not on therapy. Practical issues of giving the infant many
medications are experienced by the nursing staﬀ and the
mother. The mother has to be in a clinically reasonable
condition to manage her baby. It is important to train
another individual in the household to assist the mother.
Experience with respect to the ARVs and their dosages in the
newborn are increasing.
Zidovudine (AZT: nucleoside reverse transcriptase
[NRTI]) is the ARV that has been most studied in the
newbornfollowed bylamivudine [43].Zidovudineisgivenat
a dosage of 2mg/kg/dose four times per day, lamivudine
(3TC NRTI) at 3mg/kg/dose twice daily and lopinovir/rit-
onovir (Kaletra Protease Inhibitor [PI]) at 300mg/m2 twice
daily. Ritonovir boosts the lopinovir level. These dosages
are according to the reference given and which is currently
prescribed in South Africa. This may change in a short space
of time.
11.ManagementoftheMotherwithTBandHIV
Once TB is diagnosed in any of the clinical settings, prompt
anti-TB therapyhas tobecommencedinordertopreventthe
adverse eﬀects in the mother, fetus, and newborn. The aim is
to render the mother non-infectious [44–47].
Treatment of TB in pregnant women follows the WHO
recommendations and is the same as for the nonpregnant
based on standard therapy for 6 months and, in coinfection
with HIV prolonged to a minimum of 9 months. The ﬁrst
line drugs, isoniazid, rifampicin, ethambutol, and pyrazi-
namide in standard doses, are readily absorbed from the
maternal gastrointestinal tract and freely cross the placenta.
TheCDCrecommendationfortreatmentofTBinpregnancy
is isoniazid (INH) rifampicin (RIF) ethambutol daily for
two months followed by INH and RIF daily or RIF and
ethambutol daily for 4 months or twice weekly for 7 months,
for a total of 9 months treatment in the latter group.
Pyrazinamide (PZA) is not recommended as its eﬀects on
the fetus are unknown. HIV-infected women should receive
RIF and although the routine use of PZA in pregnancy is notInternational Journal of Pediatrics 5
recommended (in the USA), the beneﬁts of PZA in the HIV-
infected woman outweigh the unknown risks to the fetus
[48–50].Streptomycinshouldnotbeusedduetotheharmful
eﬀects on the fetus.
The recommendation for HIV positive pregnant women
with pulmonary TB classiﬁed as WHO clinical stage 111 and
1V are eligible for ARV therapy irrespective of CD4 lympho-
cyte counts. WHO clinical stage 1 and 11 are oﬀered ARV
therapy if the CD4 count is <200cells/m3 [27]. The trend
now is towards earlier ARV therapy and most guidelines
recommend treatment when the CD4 count is <350 cells/m3
[2]. All women with stage 3 or 4 irrespective of CD4 count
[51].
Inresourcelimitedsettingswomenwithsatisfactory CD4
counts are oﬀered zidovudine from 28 weeks and nevirapine
at the onset of labour as prophylaxis against mother-to-child
transmission of HIV. In developed countries it is standard
practice to oﬀer ARVs aiming at undetectable viral load
before delivery.
ARVs with concomitant TB therapy are complicated by
a high pill burden, drug toxicities, drug interactions, and
the immune reconstitution syndrome (IRIS). ARV therapy
mayexacerbate oraggravateunderlying TB(reported in20%
patients commencing ARV therapy). IRIS is more likely to
occur during the ﬁrst two months of commencing ARV
therapy if CD4 counts are <100 cells/m3 [27].
In resource-restricted settings, the ﬁrst line regimen
of NRTIs and one nonnucleoside reverse transcriptase
inhibitors (NNRTI). The preferred drugs, cheaply man-
ufactured as a ﬁxed dose tablet taken twice a day, are
stavudine (40mgs twice daily), lamivudine (300mgs daily),
and nevirapine (200mgs daily for two weeks then 200mg
twice daily). Stavudine is less favoured and options include
substitution of zidovudine for stavudine and efavirenz for
nevirapine.
WHO guidelines for 2010 include the following
possible combinations:
zidovudine + lamivudine + nevirapine,
tenofuvir + lamivudine (or emotricitabine)+ NVP
zidovudine u lamivudine + efevirenz, or
tenofuvir + lamivudine (or emtricitabine) + efavir-
enz.
Efavirenz is not recommended for the ﬁrst trimester of
pregnancy. The newborn of the mother on ART whether
breastfeeding or giving replacement feeds receives zidovu-
dine twice daily or nevirapine daily for four to six weeks of
age [51].
Drug interactions between ARVs and TB therapy pose
problems. RIF induces CYP450 which leads to a reduction of
theplasmaconcentrationofnevirapineby30%andefavirenz
by 20–25%. The clinical signiﬁcance of this is not known
but there are concerns that such reduced nevirapine levels
may induce drug resistance and treatment failure. However,
increasing nevirapine dosage for compensation for plasma
reduction, increases the risk for toxic eﬀects of the drug,
particularly hepatotoxicity [52]. The combination of RIF
and nevirapine should be avoided particularly in pregnancy.
However, it has been shown that in patients with a low
CD4 count the risk of hepatotoxicity is reduced. WHO
recommends abacavir or tenofovr instead of nevirapine but
this is an expensive option. The advantages outweigh the
disadvantages. It is suggested that RIF should be used in
the initial phase of TB therapy, isoniazid and ethambutol
is continued and HAART with nevirapine may then be
commenced. Efavirenz, much more expensive, should be
avoided in pregnancy due to concern about teratogenicity.
The duration of TB therapy in a HIV positive patient
may have to be extended to 9 months duration and there
is an ongoing risk of “second episode” of TB [40]. It is
now considered prudent to treat both TB and HIV at the
same time to avoid unnecessary deaths due to delay in
commencing therapy [53].
12.MultidrugResistantTuberculosis
Drug resistant TB is increasing worldwide as was noted by
Edlin et al. [54]. MDR TB as a cause of death in patients co-
infected with TB and HIV is well recognized [55].
Multidrug resistant (MDR) TB deﬁned as resistance to
INHandRIFwasidentiﬁedamonghospitalisedpatientswith
AIDS. Ninety to 98% of patients with MDR TB are HIV co-
infected [56]. Resistance may be primary and occurs when
an individual is infected with Mycobacterium tuberculosis
which is already resistant to a particular drug; secondary
resistance is when drug-resistance organisms emerge as
the dominant population during treatment. Risk factors
for the development of MDR TB are poor adherence and
compliance to therapy, inadequate assessment of response,
incorrect dosage or number of drugs used as prophylaxis
or treatment, previous prolonged treatment of TB, contact
with a patient known to have drug resistant disease HIV
infection and drug abuse. Patients suspected of MDR TB
should be referred to a tuberculosis centre specialized in this
condition.
T h es i d ee ﬀects of drugs lead to a risk of noncompliance
and nonadherence in therapies for both diseases increasing
the risk for the pregnant woman and her fetus/child. The
burden of pills and duration of therapies in itself poses
logistical issues, MDR TB having to be treated for two years.
Suspected MDR TB in a pregnant woman should be treated
with INH, RIF, Ethambutol, and a quinolone until culture
and sensitivities are available. The newborn baby should be
givenprophylactictherapyofhighdoseINH(15mg/kg/day),
ethionamide (10mg/kg/day), and a quinolone (10g/kg/day)
[57]. The aminoglycosides, capreomycin, pyrazinamide, and
quinolones are contraindicated in pregnancy. Newer thera-
pies include rifamycins, macrolides, clofazimine, amoxicillin
and clavulanic acid [58].
Reports of the safety of second-line drugs for MDR TB
in pregnancy have appeared, but very small numbers of chil-
dren have been followed, 7 in the short term and 6 children
for long-term evaluations [59]. The drugs appear to have no
adverse eﬀects on the children and none had acquired TB
[58, 60].6 International Journal of Pediatrics
In our setting a few pregnant women have had MDR TB,
so far their babies have been TB negative. WHO is in the
process of developing further guidelines for TB, MDR TB
and congenital TB which may change current approaches to
therapy.FromIndiaguidelineshavebeensummarizedforthe
management of pulmonary TB, extrapulmonary TB, and TB
in special circumstances [61].
13.Outcomes
13.1. Maternal Mortality. Maternal mortality in relationship
to HIV and TB was discussed in the introduction. The
following studies examine the causes of maternal death.
In a two-year retrospective study of maternal deaths at
a teaching hospital in Lusaka, Zambia, 58% of the deaths
were due infections, malaria (30%), TB (25%) respiratory
infections (22%), and other HIV-associated opportunistic
infections [62].Ina hospital-based, ﬁve-yearstudy attertiary
level in Johannesburg, South Africa, 106 maternal deaths
occurred in 36708 deliveries. Seventy percent of deaths were
HIV related, mainly TB and pneumonia. Maternal mortality
ratios in HIV infected women were 776 per 100000,
6.2-fold higher than HIV negative women, 124 per 100 000
[63].
In an autopsy study of 171 maternal deaths in Mozam-
bique, 56% of the deaths were due to nonobstetric causes,
mostlyHIV/AIDS,related infections, lungsepsis, meningitis,
malaria, and TB [64].
13.2. Obstetric, Perinatal, and Neonatal Outcomes. In earlier
studies on TB in pregnancy there was no signiﬁcant eﬀect
on outcomes [64]. This has changed due to the impact of
the HIV epidemic [2, 3]. The eﬀe c t sm a yb em o r es i g n i ﬁ c a n t
in low socioeconomic populations. If diagnosed and treated,
the eﬀects of tuberculosis on pregnancy and the neonate
are not so serious but in populations with a low socioe-
conomic status tuberculosis increases the risk of abortions
and premature delivery [65]. In studies from India, the
outcome of pulmonary tuberculosis in 79 pregnant women
compared to 316 cases matched for age and socioeconomic
status revealed infants born to women with tuberculosis
were signiﬁcantly lighter than the controls; there was a
two-fold increase in prematurity (22.8% versus 11.1%), a
small size for gestational age (20.2% versus 7.9%), and a
6-fold increase in perinatal deaths (10.1% versus 1.6%).
The adverse eﬀects were more pronounced in those cases
in which tuberculosis was diagnosed late in pregnancy,
when adherence to antituberculosis treatment was poor
and in those with advanced pulmonary disease [44]. A
similar study on 33 pregnant women with extrapulmonary
tuberculosis, showed that disease conﬁned to lymph nodes
was not associated with adverse obstetric outcomes but that
those with more serious manifestations of disease (intestinal,
skeletal, meningeal, renal, and endometrial) suﬀered similar
adverse outcomes as those with pulmonary tuberculosis
[7].
In Mexico, late diagnosis and poor care resulted in a 4-
fold increase in obstetric morbidity and a 9-fold increase in
preterm labour [46]. In a further study from that country,
the perinatal outcomes of 35 mothers with tuberculosis were
compared to those of 105 healthy mothers and revealed
that, in the former, the neonates were signiﬁcantly smaller
(2.8 versus 3.1kg) and that the relative risks of premature
delivery and perinatal death were, respectively, 2.1 and 3.1.
Poor outcomes were particularly prominent in women with
advanced pulmonary tuberculosis in late pregnancy [44]. In
Durban, South Africa, neonates of women with tuberculosis
were signiﬁcantly smaller, with 49% having a birth weight
less than 2.5kg compared to 21.8% for the overall hospital
deliveries [6].
Perinatal mortality in those mothers with tuberculosis
and HIV was 1.6-fold higher than for the King Edward
hospital, Durban and the KwaZulu Natal region.
Pregnancy in women infected with HIV-1 alone tends
to result in low birth weight premature babies, particularly
in those with advanced HIV disease [48]. The outcome of
pregnancy in those with both HIV disease and tuberculosis
is worse, but it is not entirely clear which disease has the
greater bearing on adverse outcomes. In the South African
study, followup of those infants with tuberculosis and HIV
infection showed persistent or worsening clinical signs,
with death occurring on average by the age of 9 months
[32]. At this time ARVS for the prevention of mother-to-
child transmission had not been implemented. Nevirapine
prophylaxis was introduced in 2001.
14.RapidlyProgressive Disease
Coinfections set the stage for rapid progression of HIV dis-
ease. This was shown in babies who were HIV exposed
and had tuberculosis. Treating the TB did not reduce the
mortality from HIV and all babies died by nine months of
age [32].
Another important factor is the immunological status of
the mother. Intrapartum transmission occurred in mothers
with very high viral load compared to mothers with in-
trauterinetransmission (5160000versus984000copies/ml).
Single-dose nevirapine impacts on intrapartum transmis-
sion. However disease progression was rapid with 85%
of the infants requiring ARV therapy within six months
[20].
It is important to recognize the early clinical manifesta-
tionsofHIV-infected infants intheﬁrst twomonths oflifein
ordertopreventthedisease progressing rapidly,toundertake
the HIV DNA PCR, and to commence ARVs early [66]. The
uninfected infant remains at risk of more frequent infections
and suﬀers morbidity greater than the unexposed infants in
early infancy [67].
15.Breastfeeding orFormula Feeding
Breast feeding is recommended by the American Academy
a n dt h eR e v i s e dN a t i o n a lT u b e r c u l o s i sC o n t r o li nI n d i a
[67, 68]. Tuberculosis is transmitted by the aerogenous
route; the mother with open tuberculosis can still infect
her baby if she formula-feeds her baby. However, the riskInternational Journal of Pediatrics 7
of transmission through breast milk is negligible and the
baby should be on either prophylaxis or treatment for TB.
In resource-poor settings exclusive breast feeding has to
be emphasized. However, in the more advantaged setting,
mothers can choose replacement feeding. The ﬁrst-line anti-
TB agents are excreted in milk in very small amounts have
no adverse eﬀects, and do not seem to predispose to the
development of drug resistance.
Breast milk carries a risk of transmission of HIV, how-
ever, exclusive breast feeding reduces HIV transmission
when compared to mixed feeding [68]. In addition, mixed
feeding carries a risk of increasing diarrhoeal and respiratory
infections [69]. The above is of relevance in underprivileged
communities. The risks of a higher infant mortality, severe
pneumonia and diarrhea by 6 months of age on formula
feeding were shown in the MASHI study [70]. However,
in settings where replacement feeding is feasible, aﬀordable,
and safe, HIV-infected women should be encouraged to
exclusively formula feed. This follows the WHO recommen-
dations [69].
Further support for women who are HIV positive and
who wish to breastfeed, comes from the studies indicating
that ﬂash heating of maternal milk inactivates HIV with
about a 20% loss of proteins and antibodies [70]. This
method has been shown in the neonatal unit at King Edward
VIIIth Hospital, Durban to be feasible and practical, some
mothers are undertaking ﬂash heating at home. The method
is a simple one of expressing breast milk into a “jam jar”,
closing it, placing the jar in a pot of cold water with the level
of the water two ﬁnger breadths above the level of the milk
in the jar, remove the lid of the jar, heat the water to a rapid
boil, and remove the jar. The milk is allowed to cool for 10–
15 minutes and may then be given to the baby. Milk not used
immediately may be be placed in the refrigerator and used at
the next feed. The jar has to be carefully closed and labeled
with name, date, and time.
A number of studies have shown the reduction in HIV
transmission during breast feeding using diﬀerent combina-
tions of ARV therapies.
Extended ARV prophylaxis with NVP dual therapy with
NVP and AZT for 14 weeks of life signiﬁcantly reduced
breast milk transmissions [71]. Kilewo et al. showed that
maternalHAARTfor6monthsand infant NVPfor6months
were equally eﬃcacious in reducing postnatal transmission
through breast milk at 6 months. International recommen-
dations on breastfeeding in HIV positive women may not
be recognized or accepted by health workers undertaking the
relevant counseling [72].
With the access to treatment with ARVs during preg-
nancy and the postpartum period of the newborn, the
risks of HIV transmission through maternal breast milk are
negligible[73]. Itis with concernthat in theNeonatalUnitat
KingEdward VIIIthHospital Durban,SouthAfrica, overa6-
monthperiodin2009,fromroutinemorbidityandmortality
records, it was noted that 10 very low-birth-weight infants
suﬀered necrotizing enterocolitis. All but one were formula-
fed, all were HIV exposed, two babies had gut perforations,
and one died. Three of the mothers were on ARVS believing
that the ARVs would protect their babies.
16.Social Issues
Social issues impact heavily on the management of HIV and
TB. The lack of adequate caregivers and maternal orphans
are major problem. The risks of therapies which carry a high
medicationburdenincludesnonadherence, noncompliance,
and poorer outcomes for the infected infant [27].
Both HIV and TB are associated with stigma which has
resulted in added suﬀering due to lack of disclosure, dis-
crimination, and criminalization to mention the commonest
associations with stigma. Stigma has seriously impeded the
care of patients, increased morbidities, the implementation
of programs and, in some circumstances, resulted in poor
adherence [74, 75].
In 2006, in South Africa, there was an estimated
122000 children living in an estimated 60000 child headed
households; the majority of whom were in three provinces:
Limpopo, KwaZulu Natal, and the Eastern Cape. Many
live with grandparents with their own vulnerabilities. In
some areas 45% of these children live with grand or great
grandparents. These children are exposed to risks of poor
education,littlefood,physicalandsexualabuse,prostitution,
and child labour [76].
17.Conclusion
The TB and HIV epidemics are a devastating combination
of infections resulting in severe morbidities and mortality
rates from these diseases as well as complications of the
combination of therapies. The social issues paralyse family
dynamics; stigma creates further dysfunctionality in society.
T h eo n l yh o p ei sf o rP M T C Tt ob es e e na st h em o s tc r i t i c a l
aspect ofHIVprevention;awareness ofand early recognition
of TB is the second hope which must be achieved urgently
if the millennium development goals of reducing maternal,
child, and TB mortality are to be achieved.
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